Biological behaviour and ezrin expression in canine rhabdomyosarcomas: 25 cases (1990-2012).
comparative oncology
metastasis
pathology
small animal
tumour biology
Journal
Veterinary and comparative oncology
ISSN: 1476-5829
Titre abrégé: Vet Comp Oncol
Pays: England
ID NLM: 101185242
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
24
10
2019
revised:
26
03
2020
accepted:
26
03
2020
pubmed:
5
4
2020
medline:
9
9
2021
entrez:
5
4
2020
Statut:
ppublish
Résumé
There are few published reports of canine rhabdomyosarcomas. In human paediatrics, rhabdomyosarcomas account for 5%-10% of all tumours and >50% of soft tissue sarcomas. They have an aggressive biologic behaviour; most patients develop diffuse metastatic disease. Ezrin, a cytoskeleton linker protein, has been correlated with metastasis in a number of tumours, including rhabdomyosarcomas. The goal of this study was to describe dogs with non-urinary rhabdomyosarcomas including clinical findings, ezrin expression and outcome. Twenty-five dogs with rhabdomyosarcomas were identified from two institutions' databases. Signalment, primary tumour location, cytologic and histologic findings, metastatic sites, treatments, survival time and necropsy results were recorded. Immunohistochemical staining for ezrin expression was performed on archived samples; cellular localization of ezrin was characterized. The mean and median age of all patients was 4.3 and 2 years, respectively. Subcutaneous and retrobulbar/orbital were the most common primary tumour locations. Sixteen dogs had metastatic disease at diagnosis. Three dogs presented with diffuse disease where a primary tumour could not be identified. A round cell tumour was the initial diagnosis in 32% of cases, and 76% of cases required immunohistochemistry to establish the diagnosis. The median survival was 10 days. Twenty-one cases had archived samples available for ezrin staining; all but one was positive and exhibited both membranous and cytoplasmic localization. Rhabdomyosarcomas occur in young dogs, may have a round cell appearance, and exhibit aggressive biologic behaviour. Given ezrin's defined role in metastasis, its observed expression in the tumours in this study suggest its possible role in canine rhabdomyosarcoma's aggressive biologic behaviour.
Substances chimiques
Antineoplastic Agents
0
Biomarkers, Tumor
0
Cytoskeletal Proteins
0
ezrin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
675-682Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M. Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett. 2009;279(2):126-136.
O'Brien D, Jacob AG, Qualman SJ, Chandler DS. Advances in pediatric rhabdomyosarcoma characterization and disease model development. Histol Histopathol. 2012;27(1):13-22.
Snyder LA, Michael H. Alveolar rhabdomyosarcoma in a juvenile labrador retriever: case report and literature review. J Am Anim Hosp Assoc. 2011;47(6):443-446.
da Roza MR, de Amorim RF, Carneiro FP, Benatto N, Barriviera M, Miguel MC. Aggressive spindle cell rhabdomyosarcoma in an 11-month-old boxer dog. J Vet Med Sci. 2010;72(10):1363-1366.
Murakami M, Sakai H, Iwatani N, et al. Cytologic, histologic, and immunohistochemical features of maxillofacial alveolar rhabdomyosarcoma in a juvenile dog. Vet Clin Pathol. 2010;39(1):113-118.
Yhee JY, Kim DH, Hwang DN, et al. Hematogenous metastasis of embryonal rhabdomyosarcoma originating from skeletal muscle in a young dog. J Vet Diagn Invest. 2008;20(2):243-246.
Kato Y, Notake H, Kimura J, et al. Orbital embryonal rhabdomyosarcoma with metastasis in a young dog. J Comp Pathol. 2012;147(2-3):191-194.
Chapman S, Nabity M, Calise D. What is your diagnosis? Lingual mass in a dog. Vet Clin Pathol. 2008;37(1):133-139.
Kim DY, Hodgin EC, Cho DY, Varnado JE. Juvenile rhabdomyosarcomas in two dogs. Vet Pathol. 1996;33(4):447-450.
Gerber K, Rees P. Urinary bladder botryoid rhabdomyosarcoma with widespread metastases in an 8-month-old Labrador cross dog. J S Afr Vet Assoc. 2009;80(3):199-203.
Bae IH, Kim Y, Pakhrin B, et al. Genitourinary rhabdomyosarcoma with systemic metastasis in a young dog. Vet Pathol. 2007;44(4):518-520.
Scott EM, Teixeira LB, Flanders DJ, Dubielzig RR, McLellan GJ. Canine orbital rhabdomyosarcoma: a report of 18 cases. Vet Ophthalmol. 2016;19(2):130-137.
Saab R, Spunt SL, Skapek SX. Myogenesis and rhabdomyosarcoma the Jekyll and Hyde of skeletal muscle. Curr Top Dev Biol. 2011;94:197-234.
Arndt CA, Rose PS, Folpe AL, Laack NN. Common musculoskeletal tumors of childhood and adolescence. Mayo Clin Proc. 2012;87(5):475-487.
Caserto BG. A comparative review of canine and human rhabdomyosarcoma with emphasis on classification and pathogenesis. Vet Pathol. 2013;50(5):806-826.
Morotti RA, Nicol KK, Parham DM, et al. An immunohistochemical algorithm to facilitate diagnosis and subtyping of rhabdomyosarcoma: the Children's oncology group experience. Am J Surg Pathol. 2006;30(8):962-968.
Sebire NJ, Malone M. Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. J Clin Pathol. 2003;56(6):412-416.
Morgenstern DA, Rees H, Sebire NJ, Shipley J, Anderson J. Rhabdomyosarcoma subtyping by immunohistochemical assessment of myogenin: tissue array study and review of the literature. Pathol Oncol Res. 2008;14(3):233-238.
Andreasen CB, White MR, Swayne DE, Graves GN. Desmin as a marker for canine botryoid rhabdomyosarcomas. J Comp Pathol. 1988;98(1):23-29.
Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004;10(2):175-181.
Khanna C, Wan X, Bose S, et al. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004;10(2):182-186.
Yu Y, Davicioni E, Triche TJ, Merlino G. The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis. Cancer Res. 2006;66(4):1982-1989.
Bulut G, Hong SH, Chen K, et al. Small molecule inhibitors of ezrin inhibit the invasive phenotype of osteosarcoma cells. Oncogene. 2012;31(3):269-281.
Li Q, Gao H, Xu H, et al. Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells. Tumour Biol. 2012;33(5):1493-1504.
Bruce B, Khanna G, Ren L, et al. Expression of the cytoskeleton linker protein ezrin in human cancers. Clin Exp Metastasis. 2007;24(2):69-78.
Sarrio D, Rodriguez-Pinilla SM, Dotor A, Calero F, Hardisson D, Palacios J. Abnormal ezrin localization is associated with clinicopathological features in invasive breast carcinomas. Breast Cancer Res Treat. 2006;98(1):71-79.
Nelson C, Barger A, Roady P. What is your diagnosis? Dermal mass over the ribs with metastasis to lymph nodes in a dog. Vet Clin Pathol. 2018;47(4):679-681.
Gebhard C, Gabriel C, Walter I. Morphological and immunohistochemical characterization of canine osteosarcoma spheroid cell cultures. Anat Histol Embryol. 2016;45(3):219-230.
Otrocka-Domagala I, Pazdzior-Czapula K, Gesek M, Koda M, Mikiewicz M, Mikolajczyk A. Aggressive, solid variant of alveolar rhabdomyosarcoma with cutaneous involvement in a juvenile labrador retriever. J Comp Pathol. 2015;152(2-3):177-181.
Qualman SJ, Coffin CM, Newton WA, et al. Intergroup rhabdomyosarcoma study: update for pathologists. Pediatr Dev Pathol. 1998;1(6):550-561.
Yu Y, Zeng P, Xiong J, Liu Z, Berger SL, Merlino G. Epigenetic drugs can stimulate metastasis through enhanced expression of the pro-metastatic Ezrin gene. PLoS One. 2010;5(9):e12710.